stockrow
Friday 6 November 2026
Export SNTI’s income statement to Excel — free account
Senti Biosciences, Inc.
SNTI Healthcare Biotechnology
Senti Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $22,000.00, down 99.1% from fiscal 2023.
- Revenue
- −98.7%
- EPS
- +26.8%
- Free cash flow
- −7.48%
Quarter to June 2026, against a year earlier
0.16
0.00
0.00%
Follow SNTI
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | 3 | 4 | 3 | — | 0 | 1 | (70.1%) | 0 | 0 | 10 | +676.5% | |
| Gross margin, % | — | — | — | — | — | 100.00 | 100.00 | 100.00 | — | 100.00 | 100.00 | 0.0 pt | ||||||
| EBT | — | — | — | — | — | (55) | (50) | (83) | (53) | (61) | (50) | +2.7% | ||||||
| EBT margin, % | — | — | — | — | — | (2,003.59) | (1,158.77) | (3,256.77) | 0.00 | (279,263.64) | (3,789.30) | (277,260.0) pt | ||||||
| Net income | — | 0 | — | — | — | (55) | (58) | (71) | (53) | (61) | (50) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | 9.48 | 1.64 | 0.58 | 0.00 | 0.00 | 0.04 | (89.9%) | |||||
| Earnings | — | — | — | — | — | (189.97) | (22.30) | (16.00) | (12.03) | (2.73) | (1.77) | (65.4%) | ||||||
| Cash flow | — | — | — | — | — | (118.94) | (13.36) | (11.81) | (9.01) | (1.93) | (1.22) | (64.3%) | ||||||
| Capex | — | — | — | — | — | (19.03) | (15.85) | (2.69) | 0.01 | (0.01) | 0.00 | (85.6%) | ||||||
| Free cash flow | — | — | — | — | — | (137.97) | (29.21) | (14.50) | (9.00) | (1.94) | (1.22) | (65.6%) | ||||||
| Book value | — | — | — | — | — | (382.75) | 48.74 | 15.08 | 5.58 | 0.25 | (0.11) | n/m | ||||||
| Shares, m | — | — | — | — | — | 0 | 3 | 4 | 5 | 22 | 28 | +196.4% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | — | 0.00 | 9.02 | 11.20 | — | 8.93 | 3.81 | 7.3 | ||||||
| P/B | — | — | — | — | — | 0.00 | 0.30 | 0.44 | — | 4.18 | 0.00 | 1.2 | ||||||
| EV/Sales | — | — | — | — | — | 0.00 | (13.95) | (2.46) | — | 2.67 | (1.10) | (3.4) | ||||||
| EV/FCF | — | — | — | — | — | 0.77 | 0.78 | 0.10 | — | (0.16) | 0.04 | 0.4 | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | (35) | (35) | (52) | (41) | (43) | (38) | +5.8% | |||||
| Capex | — | — | — | — | — | (6) | (41) | (12) | 0 | 0 | 0 | (57.3%) | ||||||
| Free cash flow | — | — | — | — | — | (40) | (76) | (64) | (41) | (44) | (38) | +2.1% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | 46 | 85 | 59 | 46 | 9 | (3) | (32.8%) | |||||
| Net debt | — | — | — | — | — | (55) | (98) | (36) | (48) | (16) | (6) | (26.2%) | ||||||
| Shareholders’ equity | — | — | — | — | — | (111) | 127 | 67 | 26 | 6 | (3) | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | (114.41) | (41.95) | (47.33) | (48.58) | (82.43) | (97.52) | +32.0 pt | |||||
| ROIC | — | — | — | — | — | 0.00 | (134.57) | (186.22) | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | — | — | 0.00 | (736.56) | (73.19) | (114.06) | (393.35) | (466.46) | (393.3) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | 4 | 122 | 48 | 34 | 39 | — | +76.7% | |||||
| Revenue/emp, $m | — | — | — | — | — | 0.69 | 0.04 | 0.05 | 0.00 | 0.00 | — | (83.1%) | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026
Senti Biosciences, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ACXP Acurx Pharmaceuticals, Inc. | $5.3M | — (loss-making) | — | — | n/m | −2.36% (below 0%: shrinking) | — | 0.00% | Compare |
| PCSA Heatwurx Inc. | $5.1M | — (loss-making) | — | −64.29% (below 0%: shrinking) | n/m | +20.29% (above 0%: growing) | 0.00% | 0.00% | Compare |
| SNTI Senti Biosciences, Inc. | $5.1M | — (loss-making) | — (loss-making) | −98.68% (below 0%: shrinking) | n/m | −7.48% (below 0%: shrinking) | 100.00% | (85,229.41%) | |
| PULM Pulmatrix, Inc. | $5.1M | — (loss-making) | — (loss-making) | −99.86% (below 0%: shrinking) | n/m | +41.26% (above 0%: growing) | 100.00% | 0.00% | Compare |
| CNSY Cerenome, Inc. | $5.1M | — (loss-making) | — (loss-making) | −70.43% (below 0%: shrinking) | n/m | −31.46% (below 0%: shrinking) | 100.00% | (2,203.65%) | Compare |
| IMNN Imunon, Inc. | $5.1M | — (loss-making) | — (loss-making) | 0.00% | n/m | −4.24% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| RVPH Reviva Pharmaceuticals Holdings, Inc. | $5.0M | — (loss-making) | — | — | n/m | +57.80% (above 0%: growing) | — | 0.00% | Compare |
| CDIO Cardio Diagnostics Holdings, Inc. | $5.0M | — (loss-making) | — (loss-making) | +23.79% (above 0%: growing) | n/m | +2.59% (above 0%: growing) | 100.00% | (48,193.84%) | Compare |
| CANF Can-Fite Biopharma Ltd | $4.9M | — (loss-making) | — (loss-making) | −1.18% (below 0%: shrinking) | n/m | +12.63% (above 0%: growing) | 0.00% | 0.00% | Compare |
| Median of peers | $5.1M | — | — | −32.74% | — | +7.61% | 50.00% | 0.00% |
Pay and ownership Proxy statement filed 30 April 2025
Ownership
Directors and executive officers, together
3.12%
Celadon Partners SPV
37.50%
Bayer Healthcare LLC
19.99%
Entities Affiliated with NEA
14.48%
PharmaEssentia Corp.
9.99%
Armistice Capital Master Fund Ltd.
7.17%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement